🇺🇸 FDA
Pipeline program

eptacog alfa (activated)

F7ICH-1641

Phase 3 small_molecule completed

Quick answer

eptacog alfa (activated) for Acquired Bleeding Disorder is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Acquired Bleeding Disorder
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials